Will Johnson & Johnson’s New Alzheimer’s Partnership Unlock New Potential Treatments?

Circle Connections: Mergers & Acquisitions Johnson & Johnson recently signed a deal with Evotec, a German development-stage biopharmaceutical company, going back to the drawing board in its ongoing quest to treat Alzheimer's disease. Treating Alzheimer's disease has been one of the most elusive goals in the health-care industry. Previous attempts by Johnson & Johnson, Pfizer, Elan, and Eli Lilly have woefully failed, and the root cause of the disease is still frequently debated. Current treatments address only the symptoms; To understand why Johnson & Johnson has gone back to the drawing board, we need to better . . .